Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis
- PMID: 34673022
- PMCID: PMC8941622
- DOI: 10.1016/j.chest.2021.08.081
Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis
Abstract
Background: Current guidelines recommend empirical antifungal therapy in patients with sepsis with high risk of invasive Candida infection. However, many different risk factors have been derived from multiple studies. These risk factors lack specificity, and broad application would render most ICU patients eligible for empirical antifungal therapy.
Research question: What risk factors for invasive Candida infection can be identified by a systematic review and meta-analysis?
Study design and methods: We searched PubMed, Web of Science, ScienceDirect, Biomed Central, and Cochrane and extracted the raw and adjusted OR for each risk factor associated with invasive Candida infection. We calculated pooled ORs for risk factors present in more than one study.
Results: We included 34 studies in our meta-analysis resulting in the assessment of 29 possible risk factors. Risk factors for invasive Candida infection included demographic factors, comorbid conditions, and medical interventions. Although demographic factors do not play a role for the development of invasive Candida infection, comorbid conditions (eg, HIV, Candida colonization) and medical interventions have a significant impact. The risk factors associated with the highest risk for invasive Candida infection were broad-spectrum antibiotics (OR, 5.6; 95% CI, 3.6-8.8), blood transfusion (OR, 4.9; 95% CI, 1.5-16.3), Candida colonization (OR, 4.7; 95% CI, 1.6-14.3), central venous catheter (OR, 4.7; 95% CI, 2.7-8.1), and total parenteral nutrition (OR, 4.6; 95% CI, 3.3-6.3). However, dependence between the various risk factors is probably high.
Interpretation: Our systematic review and meta-analysis identified patient- and treatment-related factors that were associated with the risk for the development of invasive Candida infection in the ICU. Most of the factors identified were either related to medical interventions during intensive care or to comorbid conditions.
Keywords: Candida; candidiasis, invasive; candidiasis, invasive/epidemiology; critical care; hospital infections; risk factors.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Figures




Similar articles
-
Candida colonization as a predictor of invasive candidiasis in non-neutropenic ICU patients with sepsis: A systematic review and meta-analysis.Int J Infect Dis. 2021 Jan;102:357-362. doi: 10.1016/j.ijid.2020.10.092. Epub 2020 Nov 3. Int J Infect Dis. 2021. PMID: 33157294
-
Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.JAMA. 2016 Oct 18;316(15):1555-1564. doi: 10.1001/jama.2016.14655. JAMA. 2016. PMID: 27706483 Clinical Trial.
-
Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime.Crit Care Med. 2015 Mar;43(3):594-602. doi: 10.1097/CCM.0000000000000746. Crit Care Med. 2015. PMID: 25493970 Clinical Trial.
-
[Epidemiological and microbiological evaluation of nosocomial infections caused by Candida species].Mikrobiyol Bul. 2012 Oct;46(4):637-48. Mikrobiyol Bul. 2012. PMID: 23188577 Turkish.
-
Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later.Intensive Care Med. 2014 Oct;40(10):1429-48. doi: 10.1007/s00134-014-3355-z. Epub 2014 Jun 17. Intensive Care Med. 2014. PMID: 24934813 Free PMC article. Review.
Cited by
-
Metabolic homeostasis in fungal infections from the perspective of pathogens, immune cells, and whole-body systems.Microbiol Mol Biol Rev. 2024 Sep 26;88(3):e0017122. doi: 10.1128/mmbr.00171-22. Epub 2024 Sep 4. Microbiol Mol Biol Rev. 2024. PMID: 39230301 Review.
-
Epidemiology of fungal infection in COVID 19 in Spain during 2020 and 2021: a nationwide study.Sci Rep. 2024 Mar 3;14(1):5203. doi: 10.1038/s41598-024-54340-1. Sci Rep. 2024. PMID: 38433130 Free PMC article.
-
Clinical Features, Outcomes, and Antifungal Susceptibility Profiles of Invasive Candida Infections in a Tertiary Care Hospital in China.Infect Drug Resist. 2025 May 5;18:2271-2282. doi: 10.2147/IDR.S510389. eCollection 2025. Infect Drug Resist. 2025. PMID: 40353202 Free PMC article.
-
The Antifungal Effects of Equol Against Candida albicans Involve Mitochondrial Dysfunction.J Fungi (Basel). 2025 Apr 27;11(5):339. doi: 10.3390/jof11050339. J Fungi (Basel). 2025. PMID: 40422673 Free PMC article.
-
Antifungal therapy of Candida biofilms: Past, present and future.Biofilm. 2023 Apr 23;5:100126. doi: 10.1016/j.bioflm.2023.100126. eCollection 2023 Dec. Biofilm. 2023. PMID: 37193227 Free PMC article.
References
-
- Goemaere B., Becker P., Van Wijngaerden E., et al. Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. Mycoses. 2018;61(2):127–133. - PubMed
-
- Bassetti M., Garnacho-Montero J., Calandra T., et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med. 2017;43(9):1225–1238. - PubMed
-
- Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41(9):1232–1239. - PubMed
-
- Kollef M., Micek S., Hampton N., Doherty J.A., Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739–1746. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources